All sponsors

Sichuan Baili Pharmaceutical Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS88
PHASE 3 / 2-334
RECRUITING45
READOUTS ≤12 MONTHS37
READOUT SLIPPED >6 MO54%

Delay Index: of 59 active trials registered more than a year ago, 32 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.0 months). See all sponsors →

Open Sichuan Baili Pharmaceutical Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
BL-M07D1
NCT06445400
P2Active, not recruitingHER2-positive Breast Cancer832025-07-21 (-10 mo)
BL-B01D1
NCT06304974
P3Active, not recruitingEsophageal Squamous Cell Carcinoma4972025-10-17 (-6 mo)
SI-B001
NCT05044897
P2Active, not recruitingHead and Neck Squamous Cell Carcinoma112025-12 (+29 mo)
GNC-038
NCT05485753
P1/2Active, not recruitingPrimary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma72025-12 (+7 mo)
SI-B001
NCT05022654
P2Active, not recruitingEsophageal Squamous Cell Carcinomas222025-12 (+27 mo)
GNC-038
NCT05192486
P1/2Active, not recruitingDiffuse Large B-cell Lymphoma122025-12 (+24 mo)
BL-M02D1
NCT05949619
P1/2Active, not recruitingNon-small Cell Lung Cancer142025-12 (+4 mo)
GNC-038
NCT05627856
P1/2Active, not recruitingNK/T Cell Lymphoma; Vascular Immunomother T Cell Lymphoma42025-12 (+13 mo)
SI-B001
NCT05020457
P2Active, not recruitingNon Small Cell Lung Cancer692025-12 (+26 mo)
GNC-035
NCT05944978
P1/2Active, not recruitingRelapsed/Refractory Chronic Lymphocytic Leukemia32025-12 (+4 mo)
SI-B001
NCT05020769
P2/3Active, not recruitingNon-small Cell Lung Cancer142025-12 (+26 mo)
BL-B01D1
NCT06382142
P3Active, not recruitingTriple-Negative Breast Cancer4182026-01-13 (-4 mo)
SI-B001
NCT05943795
P3Active, not recruitingNon-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung5892026-07
BL-B01D1
NCT06382116
P3Active, not recruitingNon-small Cell Lung Cancer4322026-08 (+3 mo)
BL-B01D1
NCT06343948
P3Active, not recruitingHR+HER2- Breast Cancer3832026-08 (+3 mo)
BL-M07D1
NCT06316531
P3Active, not recruitingHER2-positive Breast Cancer2742026-10 (+5 mo)
BL-M07D1
NCT06423885
P2Active, not recruitingHER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma642026-10 (+4 mo)
BL-B01D1 for Injection
NCT06598787
P2RecruitingRecurrent Glioblastoma202026-10
SI-B001
NCT06668961
P2Active, not recruitingHead and Neck Squamous Cell Carcinoma482026-11
BL-B01D1
NCT06118333
P3Active, not recruitingNasopharyngeal Carcinoma3862026-11 (+11 mo)
SI-B001
NCT05668858
P1/2Active, not recruitingSquamous Cell Carcinoma of Head and Neck702026-12 (+24 mo)
BL-M07D1
NCT06031584
P1/2RecruitingHer2-positive/Low-expression Urinary and Digestive Tract Tumors422026-12 (+13 mo)
SI-B001
NCT05949606
P1/2Active, not recruitingNon-small Cell Lung Cancer952026-12 (+16 mo)
BL-B01D1
NCT06405425
P2RecruitingUrothelial Carcinoma522026-12 (+7 mo)
BL-B01D1
NCT06500026
P3Active, not recruitingSmall Cell Lung Cancer7222026-12 (+5 mo)
GNC-038
NCT05623982
P1/2RecruitingNon-hodgkin's Lymphoma402026-12 (+28 mo)
BL-B01D1
NCT06471205
P2RecruitingTriple-negative Breast Cancer522026-12 (+5 mo)
BL-B01D1
NCT06382129
P3Active, not recruitingNon-small Cell Lung Cancer6982026-12 (+7 mo)
BL-B01D1
NCT06006169
P2RecruitingHead and Neck Squamous Cell Carcinoma1862026-12 (+15 mo)
SI-B001
NCT05054439
P2Active, not recruitingHead and Neck Squamous Cell Carcinoma452026-12 (+41 mo)
BL-B01D1
NCT05956587
P2RecruitingNon-small Cell Lung Cancer; Nasopharyngeal Carcinoma1212026-12 (+16 mo)
BL-B01D1
NCT06437509
P2RecruitingExtensive-stage Small-cell Lung Cancer662026-12 (+6 mo)
BL-B01D1
NCT05803018
P1/2RecruitingGynecological Malignant Tumor; Solid Tumor382026-12 (+43 mo)
GNC-035
NCT06066203
P1/2RecruitingNon-hodgkin's Lymphoma402026-12 (+13 mo)
SI-B003
NCT06008054
P2RecruitingEsophageal Cancer; Gastric Cancer3762026-12 (+15 mo)
BL-B01D1
NCT05785039
P2RecruitingUrinary System Tumor; Solid Tumor762026-12 (+20 mo)
BL-B01D1
NCT05965856
P2RecruitingUrothelial Carcinoma; Solid Tumor522026-12 (+16 mo)
BL-B01D1
NCT06042894
P2RecruitingBreast Cancer582026-12 (+13 mo)
BL-M07D1
NCT06114511
P1/2Active, not recruitingNon-small Cell Lung Cancer782026-12 (+12 mo)
BL-B01D1
NCT05924841
P2RecruitingSmall Cell Lung Cancer1002026-12 (+17 mo)
BL-B01D1
NCT05990803
P2RecruitingCervical Cancer1302026-12 (+15 mo)
BL-M07D1
NCT06131450
P1/2RecruitingGynecological Malignancies1582027-01 (+13 mo)
BL-B01D1
NCT06978114
P2RecruitingAdvanced Biliary Tract Cancer462027-05
BL-B01D1
NCT06986785
P2RecruitingAdvanced Hepatocellular Carcinoma742027-05
BL-M07D1
NCT06957886
P3RecruitingHER2-low Breast Cancer5662027-05
BL-B01D1
NCT07054567
P2RecruitingCervical Cancer; Endometrial Cancer962027-05
BL-B01D1
NCT06962787
P2RecruitingRenal Cancer2602027-05
BL-B01D1
NCT06857175
P3Active, not recruitingUrothelial Carcinoma5152027-06
BL-B01D1
NCT06475300
P2RecruitingNon-small Cell Lung Cancer; Nasopharyngeal Carcinoma5702027-06 (+11 mo)
BL-B01D1
NCT06994195
P3RecruitingEpithelial Ovarian Cancer; Fallopian Tube Cancer4502027-06
BL-B01D1
NCT06787664
P2Active, not recruitingChordoma272027-06
BL-M07D1
NCT07152405
P3RecruitingGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma4902027-06
BL-B01D1
NCT06498986
P2Active, not recruitingNon-small Cell Lung Cancer762027-06 (+10 mo)
BL-B01D1
NCT06437522
P2RecruitingHead and Neck Squamous Cell Carcinoma462027-06 (+12 mo)
BL-B01D1
NCT05880706
P2Active, not recruitingNon-small Cell Lung Cancer1982027-07 (+24 mo)
BL-M07D1
NCT07730489
P3Not yet recruitingColorectal Cancer1302027-12
BL-M07D1
NCT07264816
P2RecruitingNon-squamous Non-small Cell Lung Cancer802027-12
BL-M11D1
NCT07255872
P2/3RecruitingAcute Myeloid Leukemia2162027-12
BL-M07D1
NCT07178795
P3RecruitingNon-squamous Non-small Cell Lung Cancer4402027-12
BL-B01D1
NCT07827261
P2Not yet recruitingNon-small Cell Lung Cancer362028-12
BL-M07D1
NCT06891833
P2/3RecruitingHER2-positive Breast Cancer9852028-12
BL-M08D1
NCT07780318
P1/2RecruitingGastrointestinal Tumors; Solid Tumors602028-12
BL-M09D1
NCT07769229
P2Not yet recruitingGynecological Malignancies; Solid Tumors1262028-12
BL-M08D1
NCT07818499
P1/2Not yet recruitingDiffuse Large B-Cell Lymphoma2042028-12
BL-B01D1
NCT07641855
P2/3Not yet recruitingCastration-resistant Prostate Cancer1802028-12
BL-B01D1
NCT07648914
P3RecruitingBreast Cancer4462028-12
BL-B01D1
NCT07554456
P2/3RecruitingEsophageal Squamous Cell Carcinoma902028-12
BL-B01D1
NCT07582315
P3RecruitingBiliary Tract Cancer5382028-12
BL-M07D1
NCT07678957
P2RecruitingBreast Cancer1202028-12
BL-M07D1
NCT07545460
P3Not yet recruitingEpithelial Ovarian Cancer; Fallopian Tube Cancer4042028-12
BL-M08D1
NCT07841925
P1/2RecruitingMelanoma; Solid Tumors302028-12
BL-M07D1
NCT07606599
P3RecruitingBiliary Tract Cancer3982028-12
BL-M08D1
NCT07818486
P1/2Not yet recruitingNasopharyngeal Carcinoma (NPC); Solid Tumors302028-12
BL-M08D1
NCT07793825
P1/2Not yet recruitingGynecological Tumors; Solid Tumors902028-12
BL-B01D1
NCT06838273
P3Active, not recruitingNon-small Cell Lung Cancer7242028-12
BL-M09D1
NCT07837622
P2Not yet recruitingUrothelial Carcinoma (UC); Solid Tumors422028-12
BL-M11D1
NCT07591168
P1/2Not yet recruitingMyelodysplastic Syndromes922028-12
BL-M08D1
NCT07788950
P2Not yet recruitingHead and Neck Squamous Cell Carcinomas; Solid Tumors302028-12
BL-M07D1
NCT07518173
P3RecruitingHER2-positive Breast Cancer5962029-12
BL-B01D1
NCT07739199
P2/3RecruitingSquamous Non-small-cell Lung Cancer3262029-12
BL-B01D1
NCT07502300
P3RecruitingExtensive-stage Small-cell Lung Cancer5622029-12
BL-B01D1
NCT07729956
P3RecruitingTriple-Negative Breast Cancer (TNBC)4362029-12
BL-B01D1
NCT07739186
P2/3RecruitingNon-squamous Non-small Cell Lung Cancer1662029-12
BL-B01D1
NCT07640789
P3RecruitingNon-small Cell Lung Cancer Stage III4182030-12
BL-B01D1
NCT07797881
P2Not yet recruitingNasopharyngeal Carcinoma (NPC)602030-12
BL-M07D1
NCT06830889
P3RecruitingHER2-positive Breast Cancer14502031-10
BL-B01D1
NCT07642024
P2/3RecruitingNon-small Cell Lung Cancer902032-12
BL-B01D1
NCT07783321
P3Not yet recruitingNasopharyngeal Carcinoma (NPC)4042033-12